Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.

Dubé MC, D'Amours M, Weisnagel SJ

Diabetes, obesity & metabolism6 Sept 2017Cited by 35 (Europe PMC)

PMID28722271DOI10.1111/dom.13063PepBankPUB-28722271

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes on insulin, liraglutide had no treatment effect on HbA1c versus placebo.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide did not change HbA1c compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHbA1c
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no treatment effect on HbA1c nor on insulin dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227101
02HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide had no treatment effect on insulin dose versus placebo.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide did not change insulin dose compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeInsulin dose
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no treatment effect on HbA1c nor on insulin dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227102
03HumanRandomized controlled trialSafety outcome
In overweight adults with type 1 diabetes, liraglutide increased heart rate by about 8 beats per minute.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide raised heart rate by about 8 beats per minute.
Peptide
Liraglutide
Outcome
IncreaseHeart rate
Study
n = 15
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Measurements
Heart rate increase
8 beats per minute
liraglutide
Source sentences
Summary
Heart rate was increased by about 8 beats per minute with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227103
04HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced body weight.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 15
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227104
05HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced body mass index.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered body mass index.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 15
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227105
06HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced waist circumference.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide reduced waist size.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 15
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227106
07HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced hip circumference.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide reduced hip size.
Peptide
Liraglutide
Outcome
DecreaseHip circumference
Study
n = 15
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227107
08HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced body fatness.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide reduced body fat.
Peptide
Liraglutide
Outcome
DecreaseBody fatness
Study
n = 15
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227108
09HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced computed tomography scan abdominal and mid-thigh measurements.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide reduced belly and thigh measures on CT scans.
Peptide
Liraglutide
Outcome
DecreaseCT abdominal and mid-thigh measurements
Study
n = 15
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227109
10HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced systolic blood pressure.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 15
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227110
11HumanRandomized controlled trialEfficacy outcome
In overweight adults with type 1 diabetes, liraglutide significantly reduced diastolic blood pressure.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide lowered diastolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure
Study
n = 15
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There were significant reductions in metabolic measures: weight, body mass index, waist and hip circumferences, body fatness, computed tomography scan abdominal and mid-thigh measurements, systolic and diastolic blood pressures (all P ≤ .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227111
12HumanRandomized controlled trialSafety outcome
In overweight adults with type 1 diabetes, liraglutide did not increase time spent in hypoglycaemia.
In plain wordsIn overweight adults with type 1 diabetes, liraglutide did not increase time spent with low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeTime spent in hypoglycaemia
Study
n = 15
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 to 1.2 to 1.8 mg titration · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no increase in time spent in hypoglycaemia with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blinded cross-over fashion, 15 participants were randomly assigned (1:1) to receive placebo (saline solution) or liraglutide for 24 weeks including a 1-month titration period from 0.6 to 1.2 to 1.8 mg, in addition to their insulin.
Report a problemFND-2872227112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01787916

52 Week Trial of Liraglutide in Type 1 Diabetes

CHU de Quebec-Universite Lavaln = 15Apr 2013 to Apr 2015

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 5 Jan 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.